Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which helps in improving glycemic control and potentially leading to weight reduction.
Pre-filled Pen:
The product in the image is a pre-filled pen containing 50mg of Tirzepatide in 3ml, designed for single-patient use.
Administration:
It is administered via subcutaneous injection, typically once weekly. The box includes one multi-dose pre-filled pen and eight disposable injection needles.
Indications:
In addition to improving blood sugar levels in type 2 diabetes, it is also indicated for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia). It has also been approved for treating moderate to severe obstructive sleep apnea in obese patients.
Safety Information:
It's important to note that tirzepatide carries a boxed warning regarding the potential risk of thyroid C-cell tumors, as observed in animal studies, and is generally not prescribed if there is a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects can include gastrointestinal issues like nausea, vomiting, and diarrhea.
